title: [Clinical pharmacokinetics of viloxazine chlorhydrate. Practical implications].
abstract: Pharmacokinetic data of an antidepressant agent: Apparent half-life (T1/2 elim), time of peak plasma concentration (Tmax), bioavailability, have a major contribution to determine optimal dosage in accordance with a low modification of steady-state levels. Viloxazine is a second generation antidepressant drug with a short apparent half-life (T1/2 elim: 2 to 5 h (3.4 h), which requires once a day 3 h i.v. infusion or three intakes of 100 mg oral standard formulation. The recent development of a new 300 mg slow-release form seems justified by a best compliance. Pharmacokinetic properties [Tmax = 3 to 9 h (5.2 h), T1/2 term = 6 to 7 h], suggest once a day dosage without risk of accumulation in chronic treatment. The relationships between plasma levels and the clinical improvement were not clear in literature. The recent therapeutic use of a 300 mg slow-release tablet has not permitted to change precedent findings.
authors.affiliation: Laboratoire Pharmacocinétique, CHRU La Milétrie, Poitiers.
authors.forename: S
authors.initials: S
authors.lastname: Bouquet
authors.forename: B
authors.initials: B
authors.lastname: Vandel
authors.forename: S
authors.initials: S
authors.lastname: Guibert
authors.forename: J
authors.initials: J
authors.lastname: Lavoisy
mesh_terms: D000284:Administration, Oral; D003692:Delayed-Action Preparations; D003866:Depressive Disorder / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D007263:Infusions, Parenteral; D009025:Morpholines / Q000493:pharmacokinetics*; D014745:Viloxazine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D003692:Delayed-Action Preparations; D009025:Morpholines; D014745:Viloxazine
vernacular_title: Pharmacocinétique clinique du chlorhydrate de viloxazine. Implications pratiques.